Stanley H. Appel

Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis

A. Pestronk, J. Florence, M. Bromberg, 2011, Neurology.

Subcutaneous IGF-1 is not beneficial in 2-year ALS trial

W. Bamlet, S. Subramony, J. Mandrekar, 2008, Neurology.

HFE mutations are not strongly associated with sporadic ALS

S. Appel, D. Beers, J. Henkel, 2004, Neurology.

An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study

A. Pestronk, D. Schoenfeld, P. Andres, 2013, The Lancet Neurology.

DECREASED mRNA EXPRESSION OF TIGHT JUNCTION PROTEINS IN LUMBAR SPINAL CORDS OF PATIENTS WITH ALS

R. Bowser, S. Appel, D. Beers, 2009, Neurology.

Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis

S. Appel, D. Beers, J. Henkel, 2011, Brain : a journal of neurology.

A phase 1 proof-of-concept study evaluating safety, tolerability, and biological marker responses with combination therapy of CTLA4-Ig and interleukin-2 in amyotrophic lateral sclerosis

D. Beers, Weihua Zhao, Jinghong Wang, 2024, Frontiers in neurology.